Roche's Divarasib Cuts Lung Cancer Death Risk by 44% in Phase III Trial
Roche announced that its KRAS-targeting drug divarasib reduced the risk of death by 44% versus rival treatments in a pivotal Phase III trial for previously treated non-small cell lung cancer, with results published in the New England Journal of Medicine.
Roche has reported results from its Phase III Krascendo-1 trial showing that its experimental drug divarasib cut the risk of death by 44% compared with the two existing approved KRAS G12C inhibitors — sotorasib and adagrasib — in patients with previously treated KRAS G12C-mutated non-small cell lung cancer. The trial enrolled 338 patients. Median overall survival was nearly 18 months with divarasib versus 12 months with the control arm drugs. Divarasib also reduced the risk of disease progression or death by 42%, with a median progression-free survival of 9.8 months against 5.7 months for the control drugs. The objective response rate was 58% with divarasib versus 32% for the comparator drugs. Safety data were also favourable: only 4.8% of divarasib patients stopped treatment due to treatment-related adverse events, compared with 11.7% in the control group, and no new safety signals emerged. The results were presented at the European Society for Medical Oncology Congress and simultaneously published in the New England Journal of Medicine. Roche said it is working with health authorities to bring the treatment to patients.
